The acquisition expands Randox’s technical capabilities into the benchtop flow cytometry space, which the company says aligns with its commitment to personalized medicine and improved preventative healthcare.
“The acquisition of Cellix complements and broadens Randox’s offerings by making flow cytometry more accessible to a wider audience of scientists and clinicians,” says Dr Peter FitzGerald, managing director of Randox Laboratories. “We are looking forward to bringing together Cellix’s expertise in cytometry with our dedication to diagnostics and believe this combination will enable us to streamline workflows, resulting in better outcomes for patients.”
Vivienne Williams, CEO of Cellix adds, “Our team is very excited to be joining forces with Randox to scale access to our technology in the broader scientific community. Cellix’s dedicated team has worked hard developing impedance-based cytometry for cell analysis supported through programs including the Disruptive Technology Innovation Fund. With Randox’s strong global presence and dedication to R&D, we are looking forward to continuing development of our technology and expanding our customer footprint.”
Randox Laboratories develops innovative diagnostic solutions for hospitals, clinical, research and molecular labs, food testing, forensic toxicology, veterinary labs, and life sciences. With offices and distribution in over 145 countries, Randox offers customers improved efficiency, quality, cost-effectiveness, and flexibility. Randox is committed to revolutionizing healthcare on a global scale.
Cellix is a developer of microfluidic tools and impedance flow cytometers for cell analysis and sorting. Customers are in life science research, cell and gene therapy discovery, development, and manufacturing. With an established product portfolio of microfluidic solutions for life science research, Cellix recently launched its first product in flow cytometry: the Inish Analyser. It is a microfluidic impedance-based flow cytometer for cell counting, cell viability, and cell membrane analysis for transfection efficiencies. Cellix is an Enterprise Ireland client company and a beneficiary of the Disruptive Technology Innovation Fund.